Rose Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Allergan Creating Awareness For Game-Changing Latisse Eyelash Growth Drug

Executive Summary

Allergan is preparing a multi-pronged marketing campaign to make lash-light consumers aware of its recently approved Latisse drug; it remains to be seen how availability of a prescription product with clinically demonstrated effectiveness will impact sales of cosmetic eyelash enhancers
Advertisement

Related Content

CARGO Builds On LashActivator Success With Line Extensions
Held Off By Latisse, Lash Allure Touts Results In A Blink At Low Price Point
NovaLash Adds Peptide-Based Eyelash "Fortifier" To Its Line Of Extensions
Marketing In Brief
Image Skincare Undercuts Competition With $89 Ageless Lashes
Latisse Eyelash Stimulant Will Complement, Not Supplant, Mascara – Allergan
Jan Marini responds to Latisse
Jan Marini Explores Anti-Aging Hair-Care Frontier With Revamped Conditioner
Jan Marini Explores Anti-Aging Hair-Care Frontier With Revamped Conditioner
Jan Marini Ceases Eyelash Product Sales Due To Allergan Suit, FDA Threat
Advertisement
UsernamePublicRestriction

Register

RS015885

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel